# A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

> **NCT02486406** · PHASE2,PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 64 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** Ombitasvir/paritaprevir/ritonavir
- **DRUG:** Dasabuvir
- **DRUG:** Ribavirin
- **DRUG:** Ombitasvir mini tablet
- **DRUG:** Paritaprevir mini tablet
- **DRUG:** Ritonavir mini tablet
- **DRUG:** Dasabuvir mini tablet
- **DRUG:** Ribavirin solution

## Key facts

- **NCT ID:** NCT02486406
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-28
- **Primary completion:** 2020-11-19
- **Final completion:** 2020-11-19
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2021-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02486406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02486406, "A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02486406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*